Press Releases Keyword Search Year None2022202120202019201820172016201520142013 09/22/22 Avadel Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference DUBLIN, Ireland , Sept. 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bi... 09/07/22 Avadel Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference DUBLIN, Ireland , Sept. 07, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bi... 08/09/22 Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2022 Financial Results Received tentative approval for LUMRYZ™ (sodium oxybate) extended-release for oral suspension from F... 08/02/22 Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9 DUBLIN, Ireland , Aug. 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bio... 07/19/22 Avadel Pharmaceuticals Announces Tentative Approval of LUMRYZ™ (sodium oxybate) extended-release oral suspension - Validates the safety profile and clinical efficacy of LUMRYZ - Pursuing strategies to accelerate f... 06/29/22 Avadel Pharmaceuticals Provides Corporate Update Pursuing strategies to accelerate final approval of FT218 NDA Optimizing cost structure to fund stra... 06/03/22 Avadel Pharmaceuticals and the American Academy of Sleep Medicine Foundation Announce an Exclusive Collaboration on the 2022 Young Investigators Research Forum DUBLIN, Ireland , June 03, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bio... 06/02/22 Avadel Pharmaceuticals to Present at the Jefferies Healthcare Conference DUBLIN, Ireland , June 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bio... 05/19/22 Avadel to Present Clinical Data for FT218 at SLEEP 2022 DUBLIN, Ireland , May 19, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biop... 05/09/22 Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results FDA review of NDA for FT218 continues; launch readiness preparations on-track to support potential c... 05/02/22 Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter Financial Results on May 9 DUBLIN, Ireland , May 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biop... 04/26/22 Avadel Pharmaceuticals Provides Comment on Recent Trading Activity DUBLIN, Ireland , April 26, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bi... 04/25/22 Avadel Pharmaceuticals Announces Interim Data from the Open-Label RESTORE Study at the 2022 American Academy of Neurology Annual Meeting Results from patient preference questionnaire indicate that people with narcolepsy preferred the onc... 04/06/22 Avadel Pharmaceuticals Announces Publication of Positive Secondary Endpoint Data from Pivotal Phase 3 REST-ON Trial Once-at-bedtime FT218 demonstrated clinically meaningful improvement in assessments of disrupted nig... 03/22/22 Avadel Pharmaceuticals to Present at Upcoming Investor Conferences DUBLIN, Ireland , March 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co... 03/17/22 Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results FDA review of NDA for FT218 is ongoing; commercial and launch preparations on-track to support poten... 03/14/22 Avadel Pharmaceuticals Announces Appointment of Brandi Robinson as Senior Vice President, Corporate Affairs DUBLIN, Ireland , March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co... 03/14/22 Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 17th DUBLIN, Ireland , March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co... 03/11/22 Avadel Announces New Positive Data for Once-at-Bedtime FT218 for Narcolepsy and Once-Nightly Dosing Preference Among Patients and Clinicians at World Sleep 2022 Discrete choice experiment demonstrated that number of doses was the most important attribute drivin... 03/10/22 Avadel Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference DUBLIN, Ireland , March 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co... 03/01/22 Avadel to Present New Clinical Data at World Sleep 2022 Eight abstracts accepted for poster presentation featuring new data from the Phase 3 REST-ON clinica... 02/14/22 Avadel Pharmaceuticals Appoints Dr. Douglas Williamson as Chief Medical Officer DUBLIN, Ireland , Feb. 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com... 02/10/22 Avadel Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference DUBLIN, Ireland , Feb. 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
09/22/22 Avadel Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference DUBLIN, Ireland , Sept. 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bi...
09/07/22 Avadel Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference DUBLIN, Ireland , Sept. 07, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bi...
08/09/22 Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2022 Financial Results Received tentative approval for LUMRYZ™ (sodium oxybate) extended-release for oral suspension from F...
08/02/22 Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9 DUBLIN, Ireland , Aug. 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bio...
07/19/22 Avadel Pharmaceuticals Announces Tentative Approval of LUMRYZ™ (sodium oxybate) extended-release oral suspension - Validates the safety profile and clinical efficacy of LUMRYZ - Pursuing strategies to accelerate f...
06/29/22 Avadel Pharmaceuticals Provides Corporate Update Pursuing strategies to accelerate final approval of FT218 NDA Optimizing cost structure to fund stra...
06/03/22 Avadel Pharmaceuticals and the American Academy of Sleep Medicine Foundation Announce an Exclusive Collaboration on the 2022 Young Investigators Research Forum DUBLIN, Ireland , June 03, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bio...
06/02/22 Avadel Pharmaceuticals to Present at the Jefferies Healthcare Conference DUBLIN, Ireland , June 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bio...
05/19/22 Avadel to Present Clinical Data for FT218 at SLEEP 2022 DUBLIN, Ireland , May 19, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biop...
05/09/22 Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results FDA review of NDA for FT218 continues; launch readiness preparations on-track to support potential c...
05/02/22 Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter Financial Results on May 9 DUBLIN, Ireland , May 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biop...
04/26/22 Avadel Pharmaceuticals Provides Comment on Recent Trading Activity DUBLIN, Ireland , April 26, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bi...
04/25/22 Avadel Pharmaceuticals Announces Interim Data from the Open-Label RESTORE Study at the 2022 American Academy of Neurology Annual Meeting Results from patient preference questionnaire indicate that people with narcolepsy preferred the onc...
04/06/22 Avadel Pharmaceuticals Announces Publication of Positive Secondary Endpoint Data from Pivotal Phase 3 REST-ON Trial Once-at-bedtime FT218 demonstrated clinically meaningful improvement in assessments of disrupted nig...
03/22/22 Avadel Pharmaceuticals to Present at Upcoming Investor Conferences DUBLIN, Ireland , March 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
03/17/22 Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results FDA review of NDA for FT218 is ongoing; commercial and launch preparations on-track to support poten...
03/14/22 Avadel Pharmaceuticals Announces Appointment of Brandi Robinson as Senior Vice President, Corporate Affairs DUBLIN, Ireland , March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
03/14/22 Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 17th DUBLIN, Ireland , March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
03/11/22 Avadel Announces New Positive Data for Once-at-Bedtime FT218 for Narcolepsy and Once-Nightly Dosing Preference Among Patients and Clinicians at World Sleep 2022 Discrete choice experiment demonstrated that number of doses was the most important attribute drivin...
03/10/22 Avadel Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference DUBLIN, Ireland , March 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
03/01/22 Avadel to Present New Clinical Data at World Sleep 2022 Eight abstracts accepted for poster presentation featuring new data from the Phase 3 REST-ON clinica...
02/14/22 Avadel Pharmaceuticals Appoints Dr. Douglas Williamson as Chief Medical Officer DUBLIN, Ireland , Feb. 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
02/10/22 Avadel Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference DUBLIN, Ireland , Feb. 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
